The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

NCT01283958 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2011-01-26

No results posted yet for this study

Summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Conditions

  • Eisenmenger's Syndrome

Sponsors & Collaborators

  • Gachon University Gil Medical Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2010-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01283958 on ClinicalTrials.gov